Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 6, 2010, Pages 561-567

  Harichand Herdt, Seema ^a   O'Regan, Ruth M ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Chemotherapy; Epothilones; Ixabepilone; Metastatic breast cancer; Prognostic factors

Indexed keywords

CAPECITABINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPOTHILONE B; ESTROGEN RECEPTOR; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE;

ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; PROTEIN EXPRESSION; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL METASTASIS;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 78650016669     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181c4c6ae     Document Type: Article

References (100)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
2. Sorlie T. Molecular portraits of breast cancer: tumor subtypes as distinct disease entities. Eur J Cancer. 2004;40:2667-2675.
3. Brennan DJ, O'Brien SL, Fagan A, et al. Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. Expert Opin Biol Ther. 2005;5:1069-1083.
4. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006;11:868-877.
5. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9:606-616.
6. Kapoor A, Vogel VG. Prognostic factors for breast cancer and their use in the clinical setting. Expert Rev Anticancer Ther. 2005;5:269-281.
7. NCCN clinical practice guidelines in oncology. Breast Cancer. 2009;1. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast. pdf. Accessed April 16, 2009.
8. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin. 1997;47:28-51.
9. Pusztai L. Current status of prognostic profiling in breast cancer. Oncologist. 2008;13:350-360. (Pubitemid 351679913)
10. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat. 1998;51:227-238.
11. Rochefort H, Glondu M, Sahla ME, et al. How to target estrogen receptornegative breast cancer? Endocr Relat Cancer. 2003;10:261-266.
12. Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006;295:1658-1667.
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet. 2005; 365:1687-1717.
14. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in'breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8: 307-325.
15. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8:215-222.
16. Perez EA, Baweja M. HER2-positive breast cancer: current treatment strategies. Cancer Invest. 2008;26:545-552.
17. Ulhoa-Cintra A, Greenberg L, Geyer CE. The emerging role of lapatinib in HER2-positive breast cancer. Curr Oncol Rep. 2008;10:10-17.
18. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244.
19. Diaz LK, Cryns VL, Symmans WF, et al. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol. 2007;14:419-430.
20. Kang SP, Martel M, Harris LN. Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol. 2008;20:40-46.
21. Reis-Filho JS, Tutt AN. Triple negative tumors: A critical review. Histopathology. 2008;52:108-118.
22. Andreopoulou E, Hortobagyi GN. Prognostic factors in metastatic breast cancer: successes and challenges toward individualized therapy. J Clin Oncol. 2008;26:3660-3662.
23. Largillier R, Ferrero JM, Doyen J, et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol. 2008;19:2012-2019.
24. Levy C, Switsers O, Ollivier J, et al. Prognostic factors for survival of metastatic breast cancer (MBC): A retrospective study from 4,233 women treated in a single institution. J Clin Oncol. 2008;26(15S):abstract 1102.
25. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8:514-520.
26. Pentheroudakis G, Fountzilas G, Bafaloukos D, et al. Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat. 2005;97:237-244.
27. Imkampe A, Bendall S, Bates T. The significance of the site of recurrence to subsequent breast cancer survival. Eur J Surg Oncol. 2007;33:420-423.
28. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20:620-623.
29. Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59:271-278.
30. Elder EE, Kennedy CW, Gluch L, et al. Patterns of breast cancer relapse. Eur J Surg Oncol. 2006;32:922-927.
31. Altundag K, Bondy ML, Mirza NQ, et al. Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. Cancer. 2007;110:2640-2647.
32. Palmieri D, Smith QR, Lockman PR, et al. Brain metastases of breast cancer. Breast Dis. 2007;26:139-147.
33. Wyld L, Gutteridge E, Pinder SE, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003;89:284-290.
34. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48-58.
35. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005;205:275-292.
36. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. In: Yu D, Hung M-C, eds. Breast Cancer Chemosensitivity. Published by Landes Bioscience, Austin, TX and Springer Science + Business Media, New York, NY. 2007: 1-22.
37. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34:378-390.
38. Altmann KH. Epothilone B and its analogs-a new family of anticancer agents. Mini Rev Med Chem. 2003;3:149-158.
39. Reichenbach H, Höfle G. Discovery and development of the epothilones: A novel class of antineoplastic drugs. Drugs R D. 2008;9:1-10.
40. Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001;7:1429-1437.
41. Bode CJ, Gupta ML, Reiff EA, et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry. 2002;41:3870-3874.
42. Nettles JH, Li H, Cornett B, et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 2004;305:866-869.
43. Heinz DW, Schubert WD, Höfle G. Much anticipated-the bioactive conformation of epothilone and its binding to tubulin. Angew Chem Int Ed Engl. 2005;44:1298-1301.
44. Lee FYF, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008;63:157-166.
45. Lee FYF, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009;63: 201-212.
46. Vahdat L. Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist. 2008;13:214-221.
47. Lee JJ, Swain SM. The epothilones: translating from the laboratory to the clinic. Clin Cancer Res. 2008;14:1618-1624.
48. Denduluri N, Swain SM. Ixabepilone for the treatment of solid tumors: A review of clinical data. Expert Opin Investig Drugs. 2008;17:423-435.
49. Vahdat LT. Clinical studies with epothilones for the treatment of metastatic breast cancer. Semin Oncol. 2008;35(2 suppl 2):S22-S30.
50. Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs. 2008;17:593-599.
51. Buzdar AU. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer. 2008;8(suppl 2):S71-S78.
52. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007;25:3421-3427.
53. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007;25:3415-3420.
54. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005;23:2726-2734.
55. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007;25:3399-3406.
56. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.
57. Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer. 2008;8:234-241.
58. Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat. 2005;89(suppl 1):S9-S15.
59. Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist. 2006; 11(suppl 1):42-51.
60. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
61. Chan S, Romieu G, Huober J, et al. Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study. J Clin Oncol 2005;23(16S):abstract 581.
62. Levy C, Fumoleau P. Gemcitabine plus docetaxel: A new treatment option for anthracycline pretreated metastatic breast cancer patients? Cancer Treat Rev. 2005;31(suppl 4):S17-S22.
63. Xeloda (capecitabine) tablets prescribing information. Roche Laboratories Inc. Revised April 2006. Available at: http://www.rocheusa.com/products/ xeloda/pi.pdf. Accessed April 16, 2009.
64. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-5217.
65. Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2008; 26:2223.
66. Lee JJ, Low JA, Croarkin E, et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol. 2006;24:2084-2091.
67. Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol. 2008;6: 455-467.
68. Hortobagyi GN, Perez E, Vrdoljak C, et al. Analysis of overall survival (OS) among patients with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine C or C alone: results from two randomized phase III trials. Paper presented at: The 2008 ASCO Breast Cancer Symposium; September 5-7, 2008; Washington, DC. Abstract 186.
69. Conte P, Roche H, Perez E, et al. 2008. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies. Paper presented at: The 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 6114.
70. Yankaskas BC. Epidemiology of breast cancer in young women. Breast Dis. 2006;23:3-8.
71. Pritchard KI. Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? Eur J Cancer. 1997;33(suppl 7):S11-S14.
72. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976-983.
73. Dowsett M, Dunbier AK. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res. 2008;14:8019-8026.
74. Rugo HS. Hormonal therapy for advanced breast cancer. Hematol Oncol Clin North Am. 2007;21:273-291.
75. Mincey BA, Palmieri FM, Perez EA. Adjuvant therapy for breast cancer: recommendations for management based on consensus review and recent clinical trials. Oncologist. 2002;7:246-250.
76. Pivot XB, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: Subgroup analysis by estrogen receptor (ER) status. Paper presented at: The ASCO Breast Symposium; September 2007; San Francisco, CA. Abstract 221.
77. Rugo H, Thomas ES, Lee RK, et al. Combination therapy with ixabepilone plus capecitabine is effective in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 6069.
78. Roché H, Thomas ES, Lee RK, et al. Ixabepilone, an epothilone B analog, is effective in ER, PR, HER-2 negative (triple negative) patients (pts): data from neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol. 2006;17(suppl 9):abstract 256P.
79. Rugo HS, Roche H, Thomas E, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: A pooled analysis of patients from two large phase III clinical studies. Paper presented at: The 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 3057.
80. Available at: http://clinicaltrials.gov/ct2/show/NCT00630032. Accessed April 16, 2009.
81. Available at: http://clinicaltrials.gov/ct2/show/NCT00490646. Accessed April 16, 2009.
82. Available at: http://clinicaltrials.gov/ct2/show/NCT00077376. Accessed April 16, 2009.
83. Available at: http://clinicaltrials.gov/ct2/show/NCT00634088. Accessed April 16, 2009.
84. Available at: http://clinicaltrials.gov/ct2/show/NCT00079326. Accessed April 16, 2009.
85. Moulder S, Wang M, Gradishar W, et al. A phase II trial of trastuzumab, weekly ixabepilone (BMS-247550) and carboplatin (TIC) in patients with HER2/neu-positive (HER2-) metastatic breast cancer (MBC): A trial coordinated by the Eastern Cooperative Oncology Group (E2103). Paper presented at: The 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX. Abstract 6070.
86. Colozza M, de Azambuja E, Personeni N, et al. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007;12:253-270.
87. Jassem J, Thomas ES, Gomez HL, et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracycline and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting. Eur J Cancer Suppl. 2007;5:213[2101]
88. Yardley DA, Chan VF, Roché HH, et al. Activity of ixabepilone plus capecitabine administered as 1st/2nd line therapy for metastatic breast cancer progressing after anthracycline/taxane therapy. Paper presented at: The 4th ISC International Conference on Cancer Therapeutics; November 15-17, 2007; Toronto, Canada.
89. Vahdat L, Fein LE, Karwal MW, et al. Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone: A pooled analysis from two phase III studies. Paper presented at: The 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 6117.
90. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. J Clin Oncol. 2004;22(14S):abstract 510.
91. Paridaens R, Biganzoli L, Bruning P, et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000;18:724-733.
92. Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:58-65.
93. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17:1413-1424.
94. Yardley DA. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer. 2008;8:487-492.
95. Roche H, Li R, Ro J, et al. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: A pooled analysis from two phase III trials. Paper presented at: The 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 2015.
96. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J Clin Oncol. 2009;27(suppl 15s): Abstract 5500.
97. Available at: http://clinicaltrials.gov/ct2/show/NCT00370552. Accessed August 20, 2009.
98. Available at: http://clinicaltrials.gov/ct2/show/NCT00785291. Accessed August 20, 2009.
99. Available at: http://clinicaltrials.gov/ct2/show/NCT00825734. Accessed August 20, 2009.
100. Available at: http://clinicaltrials.gov/ct2/show/NCT00633464. Accessed August 20, 2009.